IVDT_In Vitro Diagnostics Technology

IVD Technology, Spring 2013

Issue link: http://dc.cn.ubm-us.com/i/125322

Contents of this Issue


Page 7 of 43

trends & perspectives Three IVD Products Named MDEA Finalists What do IVD products from LipoScience, HTG Molecular Diagnostics, and BioNano Genomics have in common? Remarkable design, according to those judging the Medical Design Excellence Awards (MDEA) this year. Products from these three companies are the ofcial fnalists in the IVD category of the competition for 2013. Te MDEA is the medtech industry's premier competition for medical device and diagnostic design and innovation. Tis year marks the program's 15th anniversary. MDEA judge Mark Vreeke, PhD, was the judge with the most knowledge of IVDs and played a signifcant role in determining this year's fnalists. He is a cofounder of the Chemical Angel Network, which brings together entrepreneurs and investors who are working on developing companies with a strong chemistry component. Mark vreeke, phd Vreeke ofers some thoughts on each of the three fnalist IVD products below. IVD Technology: How important is design to IVD instruments? Mark Vreeke: In the case of IVD, it's simplifying operation. Tese devices typically don't have the design cachet of other categories. In some of the other award categories it's more of a look and feel. IVD instruments in a clinical lab are essentially boxes, to be quite honest. Te design really comes into the integration of the technology into that box. 8 ivd tec HnOLO G Y | sp rin G 2013 magenta cyan yellow black the irys Genomics platform by Bionano Genomics. And then that translates to the user's experience? Yes, simplifying operations, taking fewer steps for the operator. Tat's where design comes into play. Among the feld of entries to the awards program this year, did any themes emerge? Te theme was cost-conscious activity. Tat was big, and also more of a focus on lifestyle diseases, chronic diseases, and treatment of ongoing conditions, rather than on fx-and-repair type approaches. Te target was important: what condition people were looking at. Long-term care activities, diabetes, the aging population, integrating data from diferent sources—those were the types of things I saw among entries rather than the next gee-whiz gadget for a single operation. Were these themes diferent from previous years that you have judged this competition? Yes, I think so. I kind of look at it as stemming from the economic downturn. Innovation was pushed back a little bit, and cost consciousness became more of an issue. It changed the research focus. Te fnalists in the IVD category were LipoScience's Vantera Clinical Analyzer, HTG Molecular Diagnostics's EDGE Platform for qNPA Molecular Technology, and BioNano Genomics's Irys Genomics Platform. Could you start by telling us what stood out for you about LipoScience's analyzer? What I like about the NMR instrument is that the company has taken a lab instrument that requires a lot of hands-on support—tuning and tweaking to get good NMR data—and turned it into a turnkey system where you can basically load up samples and queue them up and run them. It takes a lot of that highly skilled expertise out of the equation. Typically an NMR requires almost a PhD to operate. Te company designed a streamlined platform where a lot of those underlying technical details were automated by i v d t e c hnol ogy. com ES236961_IV1305_008.pgs 04.24.2013 23:37 UBM

Articles in this issue

Links on this page

Archives of this issue

view archives of IVDT_In Vitro Diagnostics Technology - IVD Technology, Spring 2013